Ligia Maria Cruz Espinoza

Ligia Maria Cruz Espinoza

Auto-generated profile, based on publicly available information

Ligia Maria Cruz Espinoza

International Vaccine Institute , Seoul

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 March 2021 in Vaccines
Verified
Journal Article
Open access
PDF file
AHAndrea Haselbeck
Andrea Haselbeck
BTBirkneh Tilahun Tadesse
Birkneh Tilahun Tadesse
JPJuyeon Park
Juyeon Park
MGMalick M. Gibani
Malick M. Gibani
LELigia María Cruz Espinoza
Ligia María Cruz Espinoza
FMFlorian Marks
Florian Marks
Typhoid fever remains a significant health problem in sub-Saharan Africa, with incidence rates of >100 cases per 100,000 person-years of observation. Despite the prequalification of safe and effective typhoid conjugate vaccines (TCV), some uncertainties remain around future demand. Real-life effectiveness data, which inform public health programs on the impact of TCVs in reducing typhoid-related mortality and morbidity, from an African setting may help encourage the introduction of TCVs in high-burden settings. Here, we describe a cluster-randomized trial to investigate population-level protection of TYPBAR-TCV®, a Vi-polysaccharide conjugated to a tetanus-toxoid protein carrier (Vi-TT) against blood-culture-confirmed typhoid fever, and the synthesis of health economic evidence to inform policy decisions. A total of 80 geographically distinct clusters are delineated within the Agogo district of the Asante Akim region in Ghana. Clusters are randomized to the intervention arm receiving Vi-TT or a control arm receiving the meningococcal A conjugate vaccine. The primary study endpoint is the total protection of Vi-TT against blood-culture-confirmed typhoid fever. Total, direct, and indirect protection are measured as secondary outcomes. Blood-culture-based enhanced surveillance enables the estimation of incidence rates in the intervention and control clusters. Evaluation of the real-world impact of TCVs and evidence synthesis improve the uptake of prequalified/licensed safe and effective typhoid vaccines in public health programs of high burden settings. This trial is registered at the Pan African Clinical Trial Registry, accessible at Pan African Clinical Trials Registry (ID: PACTR202011804563392).

15 June 2025 in Clinical Infectious Diseases
Verified
Journal Article
Open access
CKCara Lynn Kim
Cara Lynn Kim
TTThaint Thaint Thwe
Thaint Thaint Thwe
LELigia M Cruz Espinoza
Ligia M Cruz Espinoza
JSJonathan D Sugimoto
Jonathan D Sugimoto
MFMosoka P Fallah
Mosoka P Fallah
BTBirkneh Tilahun Tadesse
Birkneh Tilahun Tadesse
Before the onset of the coronavirus disease 2019 (COVID-19) pandemic, the African region already faced a substantial communicable disease burden and a rising prevalence of noncommunicable and chronic conditions. The COVID-19 pandemic has underscored critical vulnerabilities within the health systems in African countries and highlighted the urgent need for self-sufficiency to increase resilience in vaccine manufacturing and clinical trial capacity. In response, substantial efforts are underway to develop vaccine and pharmaceutical manufacturing capabilities across the continent. Ongoing initiatives supported by large donor organizations are aimed at initiating much-needed progress toward greater self-sufficiency in vaccine production in Africa, as coordinated by the Africa Centers for Disease Control. Continued investment, regulatory harmonization, and strengthened international and regional partnerships are essential for Africa to develop sustainable vaccine manufacturing.

14 November 2021 in Pathogens
Verified
Journal Article
Open access
PDF file
CKChristian Keller
Christian Keller
RRRaphaël Rakotozandrindrainy
Raphaël Rakotozandrindrainy
VKVera von Kalckreuth
Vera von Kalckreuth
JHJean Noël Heriniaina
Jean Noël Heriniaina
NSNorbert Georg Schwarz
Norbert Georg Schwarz
FMFlorian Marks
Florian Marks
Rickettsiae may cause febrile infections in humans in tropical and subtropical regions. From Madagascar, no molecular data on the role of rickettsioses in febrile patients are available. Blood samples from patients presenting with fever in the area of the capital Antananarivo were screened for the presence of rickettsial DNA. EDTA (ethylenediaminetetraacetic acid) blood from 1020 patients presenting with pyrexia > 38.5 °C was analyzed by gltA-specific qPCR. Positive samples were confirmed by ompB-specific qPCR. From confirmed samples, the gltA amplicons were sequenced and subjected to phylogenetic analysis. From five gltA-reactive samples, two were confirmed by ompB-specific qPCR. The gltA sequence in the sample taken from a 38-year-old female showed 100% homology with R. typhi. The other sample taken from a 1.5-year-old infant was 100% homologous to R. felis. Tick-borne rickettsiae were not identified. The overall rate of febrile patients with molecular evidence for a rickettsial infection from the Madagascan study site was 0.2% (2/1020 patients). Flea-borne rickettsiosis is a rare but neglected cause of infection in Madagascar. Accurate diagnosis may prompt adequate antimicrobial treatment.

8 November 2021 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Open access
PDF file
BGBrian Grundy
Brian Grundy
UPUrsula Panzner
Ursula Panzner
JLJie Liu
Jie Liu
HJHyon Jin Jeon
Hyon Jin Jeon
JIJustin Im
Justin Im
FMFlorian Marks
Florian Marks
: Quantitative polymerase chain reaction (qPCR) of dried blood spots (DBS) for pathogen detection is a potentially convenient method for infectious disease diagnosis. This study tested 115 DBS samples paired with whole blood specimens of children and adolescent from Burkina Faso, Sudan, and Madagascar by qPCR for a wide range of pathogens, including protozoans, helminths, fungi, bacteria, and viruses. Plasmodium spp. was consistently detected from DBS but yielded a mean cycle threshold (Ct) 5.7 ± 1.6 higher than that from whole blood samples. A DBS qPCR Ct cutoff of 27 yielded 94.1% sensitivity and 95.1% specificity against the whole blood qPCR cutoff of 21 that has been previously suggested for malaria diagnosis. For other pathogens investigated, DBS testing yielded a sensitivity of only 8.5% but a specificity of 98.6% compared with whole blood qPCR. In sum, direct PCR of DBS had reasonable performance for Plasmodium but requires further investigation for the other pathogens assessed in this study.